Ultrathin-strut versus thin-strut drug-eluting stents for primary PCI: a subgroup analysis of the BIOSTEMI randomized trial

Iglesias, Juan Fernando; Muller, Olivier; Losdat, Sylvain; Roffi, Marco; Kurz, David J; Weilenmann, Daniel; Kaiser, Christoph; Valgimigli, Marco; Windecker, Stephan; Pilgrim, Thomas

doi:10.1016/j.jcin.2020.07.038

Scientific article

Letter

Open access

English

Ultrathin-strut versus thin-strut drug-eluting stents for primary PCI: a subgroup analysis of the BIOSTEMI randomized trial

ContributorsIglesias, Juan Fernando; Muller, Olivier; Losdat, Sylvain; Roffi, Marco; Kurz, David J; Weilenmann, Daniel; Kaiser, Christoph; Valgimigli, Marco; Windecker, Stephan; Pilgrim, Thomas

Published inJACC. Cardiovascular interventions, vol. 13, no. 19, p. 2314-2316

Publication date2020-10-12

Keywords

Absorbable Implants
Coronary Artery Disease / therapy
Drug-Eluting Stents
Everolimus
Humans
Percutaneous Coronary Intervention
Prosthesis Design
Sirolimus
Treatment Outcome

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Citation (ISO format)

IGLESIAS, Juan Fernando et al. Ultrathin-strut versus thin-strut drug-eluting stents for primary PCI: a subgroup analysis of the BIOSTEMI randomized trial. In: JACC. Cardiovascular interventions, 2020, vol. 13, n° 19, p. 2314–2316. doi: 10.1016/j.jcin.2020.07.038

Article (Published version)

OA OTHER

Identifiers

PID : unige:161613
DOI : 10.1016/j.jcin.2020.07.038
PMID : 33032722

ISSN of the journal1876-7605

59views

15downloads

Creation02/21/2022 3:34:00 PM

First validation02/21/2022 3:34:00 PM

Update time03/16/2023 6:49:58 AM

Status update03/16/2023 6:49:57 AM

Last indexation10/19/2023 6:17:31 PM

Archive ouverte UNIGE

Ultrathin-strut versus thin-strut drug-eluting stents for primary PCI: a subgroup analysis of the BIOSTEMI randomized trial

Technical informations